These G-CSF + ISO mobilized grafts exhibited distinct gene expression profiles and enriched pathways associated with anti-tumor activity, which correlated with enhanced in vitro cytotoxicity against the K562 chronic myeloid leukemia cell line. The gene discussed is CSF3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.